[Seroprevalence of Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) in a sample of patients diagnosed with Alcohol User Disorder in Albacete (Spain).] / Seroprevalencia del virus de la hepatitis B, del virus de la hepatitis C y del virus de la inmunodeficiencia humana en una muestra de pacientes diagnosticados de trastorno por consumo de alcohol en Albacete.

OBJECTIVE: Studies report a higher prevalence of HCV, HBV and HIV in the population with Alcohol Use Disorder. Our objective is to determine the seroprevalence for hepatitis B and C and the human immunodeficiency virus (HIV) in patients with alcohol use disorder, as well as to determine if there is a correct serological screening of these. METHODS: Retrospective study of 204 patients with Alcohol Use Disorder followed up in the Addictive Behaviors Unit from Albacete. They started treatment from 2013-2014 onwards, the last patient was recruited in December of 2017. RESULTS: Our sample has 160 men (78.4%) and 44 women (21.6%). The median age is 46.2 years. 161 patients (78.9%) had HIV serology and it was negative in all. 146 patients (71.6%) had negative hepatitis B serology and 12 (5.9%) were vaccinated. 36 patients (17.6%) had no hepatitis B serology performed. In 10 patients, hepatitis B serology was positive (4.9%; 95% CI 1.9-7.9%). 159 patients (77.9%) had negative hepatitis C serology, and 37 patients had not performed it (18.1%). 8 patients had positive serology (prevalence of 3.9%; 95% CI 1.2-6.6%). Excluding patients who did not have serology, seroprevalence was 5.9% (95% CI 2.3-9.6%) and 4.8% (95% CI 1.5-8.1%) respectively. Failure to perform serologies was associated with older age and less weekly Standard Drink Units (SDUs) consumption. CONCLUSIONS: The seroprevalence of HBV and HCV in patients with alcohol use disorder is high. It should be ensured that 100% of patients with alcohol use disorder undergo HCV, HIV, HBV serology, reducing the loss of diagnostic opportunities.

OBJETIVO: Estudios relatan mayor prevalencia de VHC, VHB y VIH en población con Trastorno de Consumo de Alcohol. El objetivo de nuestro estudio fue determinar la seroprevalencia para Virus de Hepatitis B (VHB), Virus de Hepatitis C (VHC) y el Virus de la Inmunodeficiencia Humana (VIH) en pacientes con trastorno por consumo de alcohol, así como determinar si existe un correcto cribaje serológico de éstos. METODOS: Estudio retrospectivo de 204 pacientes con trastorno por consumo de alcohol seguidos en la unidad de conductas adictivas de Albacete, que iniciaron tratamiento desde el año 2013-2014 en adelante, el último paciente fue reclutado en diciembre de 2017. RESULTADOS: Nuestra muestra tiene 160 hombres (78,4%) y 44 mujeres (21,6%). La mediana de edad es 46,2 años. 161 pacientes (78,9%) tenían serología de VIH y fue negativa en todos. 146 pacientes (71,6%) tenían serología negativa de hepatitis B y 12 (5,9%) estaban vacunados. 36 pacientes (17,6%) no tenían serología realizada de hepatitis B. En 10 pacientes la serología de hepatitis B fue positiva (4,9%; IC95% 1,9-7,9%). 159 pacientes (77,9%) tenían serología negativa de hepatitis C, y 37 pacientes no la tenían realizada (18,1%). 8 pacientes tenían serología positiva (prevalencia de 3,9%; IC95% 1,2-6,6%). Excluyendo a los pacientes que no tenían serología la seroprevalencia fue de 5,9% (IC95% 2,3-9,6%) y de 4.8% (IC95% de 1,5-8,1%) respectivamente. La no realización de serologías se asoció a mayor edad y un menor consumo de Unidades de Bebida Estándar (UBEs) por semana. CONCLUSIONES: La seroprevalencia de VHB y VHC en pacientes con trastorno por consumo de alcohol es alta. Debería asegurarse que el 100% de pacientes con trastorno de consumo de alcohol, se realicen serologías de VHC, VIH, VHB disminuyendo pérdida de oportunidades diagnósticas.

Seroprevalencia del virus dela hepatitis B, del virus de la hepatitis Cy del virus de la inmunodeficienciahumana en una muestra de pacientesdiagnosticados de trastorno porconsumo de alcohol en Albacete / Seroprevalence of Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) in a sample of patients diagnosed with Alcohol User Disorder in Albacete (Spain)

FUNDAMENTOS: Estudios relatan mayor prevalencia de VHC, VHB y VIH en población con Trastorno de Consumo de Alcohol. Elobjetivo de nuestro estudio fue determinar la seroprevalencia para Virus de Hepatitis B (VHB), Virus de Hepatitis C (VHC) y el Virus dela Inmunodeficiencia Humana (VIH) en pacientes con trastorno por consumo de alcohol, así como determinar si existe un correctocribaje serológico de éstos.MÉTODOS : Estudio retrospectivo de 204 pacientes con trastorno por consumo de alcohol seguidos en la unidad de conductas adic-tivas de Albacete, que iniciaron tratamiento desde el año 2013-2014 en adelante, el último paciente fue reclutado en diciembre de 2017.RESULTADOS: Nuestra muestra tiene 160 hombres (78,4%) y 44 mujeres (21,6%). La mediana de edad es 46,2 años. 161 pacientes(78,9%) tenían serología de VIH y fue negativa en todos. 146 pacientes (71,6%) tenían serología negativa de hepatitis B y 12 (5,9%)estaban vacunados. 36 pacientes (17,6%) no tenían serología realizada de hepatitis B. En 10 pacientes la serología de hepatitis B fuepositiva (4,9%; IC95% 1,9-7,9%). 159 pacientes (77,9%) tenían serología negativa de hepatitis C, y 37 pacientes no la tenían realizada(18,1%). 8 pacientes tenían serología positiva (prevalencia de 3,9%; IC95% 1,2-6,6%). Excluyendo a los pacientes que no tenían serolo-gía la seroprevalencia fue de 5,9% (IC95% 2,3-9,6%) y de 4.8% (IC95% de 1,5-8,1%) respectivamente. La no realización de serologíasse asoció a mayor edad y un menor consumo de Unidades de Bebida Estándar (UBEs) por semana.CONCLUSIONES: La seroprevalencia de VHB y VHC en pacientes con trastorno por consumo de alcohol es alta. Debería asegurarseque el 100% de pacientes con trastorno de consumo de alcohol, se realicen serologías de VHC, VIH, VHB disminuyendo pérdida deoportunidades diagnósticas.(AU)

BACKGROUND: Studies report a higher prevalence of HCV, HBV and HIV in the population with Alcohol Use Disorder. Our objectiveis to determine the seroprevalence for hepatitis B and C and the human immunodeficiency virus (HIV) in patients with alcohol usedisorder, as well as to determine if there is a correct serological screening of these.METHODS: Retrospective study of 204 patients with Alcohol Use Disorder followed up in the Addictive Behaviors Unit from Albacete.They started treatment from 2013-2014 onwards, the last patient was recruited in December of 2017.RESULTS: Our sample has 160 men (78.4%) and 44 women (21.6%). The median age is 46.2 years. 161 patients (78.9%) had HIV sero-logy and it was negative in all. 146 patients (71.6%) had negative hepatitis B serology and 12 (5.9%) were vaccinated. 36 patients (17.6%)had no hepatitis B serology performed. In 10 patients, hepatitis B serology was positive (4.9%; 95% CI 1.9-7.9%). 159 patients (77.9%)had negative hepatitis C serology, and 37 patients had not performed it (18.1%). 8 patients had positive serology (prevalence of 3.9%;95% CI 1.2-6.6%). Excluding patients who did not have serology, seroprevalence was 5.9% (95% CI 2.3-9.6%) and 4.8% (95% CI 1.5-8.1%)respectively. Failure to perform serologies was associated with older age and less weekly Standard Drink Units (SDUs) consumption.CONCLUSIONS: The seroprevalence of HBV and HCV in patients with alcohol use disorder is high. It should be ensured that 100%of patients with alcohol use disorder undergo HCV, HIV, HBV serology, reducing the loss of diagnostic opportunities.(AU)

Common Laboratory Parameters Are Useful for Screening for Alcohol Use Disorder: Designing a Predictive Model Using Machine Learning.

The diagnosis of alcohol use disorder (AUD) remains a difficult challenge, and some patients may not be adequately diagnosed. This study aims to identify an optimum combination of laboratory markers to detect alcohol consumption, using data science. An analytical observational study was conducted with 337 subjects (253 men and 83 women, with a mean age of 44 years (10.61 Standard Deviation (SD)). The first group included 204 participants being treated in the Addictive Behaviors Unit (ABU) from Albacete (Spain). They met the diagnostic criteria for AUD specified in the Diagnostic and Statistical Manual of mental disorders fifth edition (DSM-5). The second group included 133 blood donors (people with no risk of AUD), recruited by cross-section. All participants were also divided in two groups according to the WHO classification for risk of alcohol consumption in Spain, that is, males drinking more than 28 standard drink units (SDUs) or women drinking more than 17 SDUs. Medical history and laboratory markers were selected from our hospital's database. A correlation between alterations in laboratory markers and the amount of alcohol consumed was established. We then created three predicted models (with logistic regression, classification tree, and Bayesian network) to detect risk of alcohol consumption by using laboratory markers as predictive features. For the execution of the selection of variables and the creation and validation of predictive models, two tools were used: the scikit-learn library for Python, and the Weka application. The logistic regression model provided a maximum AUD prediction accuracy of 85.07%. Secondly, the classification tree provided a lower accuracy of 79.4%, but easier interpretation. Finally, the Naive Bayes network had an accuracy of 87.46%. The combination of several common biochemical markers and the use of data science can enhance detection of AUD, helping to prevent future medical complications derived from AUD.